Showing 41-50 of 2009 results for "".
Laser Tattoo Removal and the Use of Stacked Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-tattoo-removal-and-the-use-of-stacked-treatments/19309/Tattoo removal procedures have been offered since the late 1990's, but are more effective than ever. This improvement is due to the implementation of stack treatments, during which four sessions can be performed at one time. To show the advances in this procedure, Dr. Joel Schlessinger walks you thrLex Icon: Lexington's Randy Waldman Speaks the Language of Successful Site Planning with Joel L. Cohen
https://practicaldermatology.com/topics/practice-management/lex-icon-lexington-s-randy-waldman-speaks-the-language-of-successful-site-planning-with-joel-l-cohen--ovevisoh/18901/How do you plan a brand new, state-of-the art surgical and clinical space that's accessible yet feels exclusive? Should you rent or buy? How do you balance your time? S. Randolph Waldman, MD answers these questions and more from series host Joel L. Cohen, MD in this edition of Best Practices.Keloids: To Cut or Not to Cut
https://practicaldermatology.com/topics/skin-cancer-photoprotection/keloids-to-cut-or-not-to-cut/19987/When treating keloids, ask patients what they want to achieve. Are they hoping to decrease itch or pain? Do they want to flatten or soften the appearance of a keloid? Hilary Baldwin, MD reviews her approach to deciding whether to remove a keloid surgically as well as other treatment options. Plus, sJoel Schlessinger MD Discusses Personal Phones in the Office
https://practicaldermatology.com/topics/practice-management/joel-schlessinger-md-discusses-personal-phones-in-the-office-/19276/Dealing with personal phone use at work is an issue that almost every business must consider. While it is important that people are available in case of an emergency, this rule can often be abused. In this video, Joel Schlessinger MD offers his advice on dealing with this office issue. Dr. Joel SImproving Dermatologic Care and Access for Gender and Sexual Minority Patients
https://practicaldermatology.com/conferences/aad-2021/improving-dermatologic-care-and-access-for-gender-and-sexual-minority-patients/19919/Dermatologists need increased knowledge of health disparities and tools to best meet the needs of sexual and gender minority patients. From increased risk of skin cancer in sexual minority individuals to acne in the transgender population, there are many dermatologic concerns arising for patients, sRobert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sComorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.